17 completed. 17 Phase 1, 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 17 | Completed 17 |
| Phase 2 | 7 | Completed 7 |
Follow Peanut Allergy: new trials by email Literature Review of Peanut Allergy trials Research Report on Peanut Allergy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IGNX001 IGNX001, Placebo - Peanut Allergy | Phase 1 | Completed | IgGenix Australia Pty Ltd | 32 | 2024-09-01 | 2025-11-14 |
| Peanut Sublingual Immunotherapy (SLIT)-Tablet for Treatment of Peanut Allergy Peanut SLIT-tablet, Placebo - Peanut Allergy | Phase 1 / Phase 2 | Completed | ALK-Abelló A/S | 209 | 2022-09-07 | 2026-05-11 |
| Pinpoint Trial: Prebiotics IN Peanut Oral ImmunoTherapy Prebiotic, Placebo - Peanut Allergy | Phase 1 / Phase 2 | Completed | University of Chicago | 20 | 2021-11-30 | 2026-03-09 |
| OMEGA Study: A Study of the Safety and Feasibility of Up-titration With INT301 in Adults With Sensitivity to Peanut INT301, Placebo - Peanut Allergy | Phase 1 | Completed | Intrommune Therapeutics | 32 | 2021-05-15 | 2023-07-28 |
| A Study to Evaluate Safety, Tolerability and Immune Response in Adolescents Allergic to Peanut After Receiving Intradermal Administration of ASP0892 (ARA-LAMP-vax), a Single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein DNA Plasmid Vaccine ASP0892, Placebo - Peanut Allergy | Phase 1 | Completed | Astellas Pharma Global Development, Inc. | 20 | 2019-03-12 | 2024-10-23 |
| Salvage Peanut Oral Immunotherapy Study Peanut OIT - Peanut Allergy | Phase 1 / Phase 2 | Completed | University of North Carolina, Chapel Hill | 15 | 2018-01-03 | 2023-01-30 |
| A Study to Assess the Biological Potency of Peanut Allergen Extract in Adolescent and Adult Peanut Allergic Subjects DBV712 IHRP - Peanut Allergy | Phase 1 | Completed | DBV Technologies | 27 | 2017-11-24 | 2019-07-26 |
| Evaluating the Safety and Efficacy of Oral Encapsulated Fecal Microbiota Transplant in Peanut Allergic Patients Fecal Microbiota Capsule - Peanut Allergy | Phase 1 | Completed | Rima Rachid | 15 | 2017-03-03 | 2026-10-08 |
| A Study to Evaluate Safety, Tolerability and Immune Response in Adults Allergic to Peanut After Receiving Intradermal or Intramuscular Administration of ASP0892 (ARA-LAMP-vax), a Single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein DNA Plasmid Vaccine ASP0892 Intradermal, ASP0892 Intramuscular, Placebo Intradermal - Peanut Allergy | Phase 1 | Completed | Astellas Pharma Global Development, Inc. | 31 | 2016-12-13 | 2024-10-23 |
| HAL-MPE1 Safety and Tolerability Study HAL-MPE1, HAL-MPE1 placebo - Peanut Allergy | Phase 1 | Completed | HAL Allergy | 42 | 2016-12-01 | 2020-02-19 |
| HAL-MPE1 First-in-human HAL-MPE1, Placebo - Peanut Allergy | Phase 1 | Completed | HAL Allergy | 17 | 2014-06-01 | 2015-07-10 |
| Tolerance Following Peanut Oral Immunotherapy Peanut Flour, Oat Flour - Peanut Allergy | Phase 1 / Phase 2 | Completed | Massachusetts General Hospital | 41 | 2013-08-01 | 2021-07-28 |
| Peanut Reactivity Reduced by Oral Tolerance in an Anti-IgE Clinical Trial Omalizumab, placebo - Peanut Allergy, Food Allergy | Phase 1 / Phase 2 | Completed | Boston Children's Hospital | 36 | 2013-01-01 | 2023-02-21 |
| Sublingual Immunotherapy for Peanut Allergy and Induction of Tolerance Liquid peanut extract (Peanut SLIT) - Peanut Hypersensitivity, Food Hypersensitivity | Phase 1 / Phase 2 | Completed | University of North Carolina, Chapel Hill | 54 | 2011-06-01 | 2019-06-12 |
| Xolair Enhances Oral Desensitization in Peanut Allergic Patients Omalizumab - Peanut Allergy | Phase 1 / Phase 2 | Completed | Lynda Schneider | 13 | 2011-02-01 | 2015-04-07 |
| Safety of Epicutaneous Immunotherapy for the Treatment of Peanut Allergy Whole peanut extract, Placebo formulation - Peanut Allergy | Phase 1 | Completed | DBV Technologies | 100 | 2010-07-01 | 2012-03-23 |
| Study of Tolerance to Oral Peanut Peanut oral immunotherapy - Peanut Allergy | Phase 1 | Completed | Cambridge University Hospitals NHS Foundation Trust | 22 | 2008-01-01 | 2015-01-14 |
Peanut Hypersensitivity (17) · Food Hypersensitivity (7) · Anaphylaxis (2) · Hypersensitivity (2) · Hypersensitivity, Immediate (1)
Immune System Diseases (17) · Nut and Peanut Hypersensitivity (17) · Hypersensitivity, Immediate (16) · Hypersensitivity (15) · Food Hypersensitivity (10)
Omalizumab (2) · Fecal Microbiota Transplantation (1) · Prebiotics (1)
Astellas Pharma Global Development, Inc. (2) · DBV Technologies (2) · HAL Allergy (2) · University of North Carolina, Chapel Hill (2) · ALK-Abelló A/S (1) · Boston Children's Hospital (1) · Cambridge University Hospitals NHS Foundation Trust (1) · IgGenix Australia Pty Ltd (1) · Intrommune Therapeutics (1) · Lynda Schneider (1) · Massachusetts General Hospital (1) · Rima Rachid (1) · University of Chicago (1)
United States (14) · Canada (2) · Australia (1) · Denmark (1) · United Kingdom (1)
Edwin Kim, MD (3) · Andrew MacGinnitie, MD, PhD (1) · Andrew T Clark, MB BD MD (1) · Carsten Bindslev-Jensen, Prof. Dr. (1) · Christina E Ciaccio, MD (1) · Jacqueline Pongracic, MD (1) · Jonathan Spergel, MD, PhD (1) · Kari Nadeau, MD, PhD (1) · Lynda C Schneider, MD (1) · Lynda Schneider, MD (1) · Rima Rachid, MD (1) · Rima T Rachid, MD (1) · Robert Wood, MD (1) · Scott Sicherer, MD (1)
PMID 32414772, PMID 38010254, PMID 19226304, PMID 21414048, PMID 26920463, PMID 29700872, PMID 31676085, PMID 33463542, PMID 34755130, PMID 34813505, PMID 39842774
R01AT004435 (1), U19AI095261 (1)